Skip to main
ALLR
ALLR logo

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc. is recognized for its attractive current valuation, with significant upside potential suggested by a revised Net Present Value (NPV) analysis estimating a twelve-month price target increase from $9.00 to $9.25. The clinical-stage company's lead product, stenoparib, has demonstrated promising and durable benefits for patients facing advanced recurrent ovarian cancer, a group with limited treatment alternatives. Furthermore, the use of proprietary Drug Response Predictor technology aims to enhance patient selection, potentially leading to improved clinical outcomes and reinforcing the company's growth prospects.

Bears say

Allarity Therapeutics reported a net loss of $2.37 million, equating to an earnings per share (EPS) of $(0.15), which fell short of expectations of $(0.21). The company's financial outlook is negatively impacted by significant balance sheet and liquidity risks, alongside uncertainties regarding the safety and efficacy of its product candidates in clinical trials and post-market settings. Furthermore, challenges related to regulatory approvals, commercialization efforts, competition, and macroeconomic factors further contribute to concerns surrounding the company's ability to achieve sustainable profitability.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.